Ongoing important trials
CIRCULATE-Japan — ctDNA MRD-guided colorectal strategies
CIRCULATE-Japan: Circulating Tumor DNA-Guided Adaptive Therapy for Colorectal Cancer
- Phase
- N/A
- Recruitment
- Active, not recruiting
- Results maturity
- Interim analysis
- Publication
- Congress + peer-reviewed
- Regulatory approval
- No regulatory approval
- NCT
- NCT05384769
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? Adjusting extra treatment based on leftover cancer DNA in blood is being studied in large Japan-led programs.
Why promising? Large-scale ctDNA-MRD platform opening adjuvant intensification/de-escalation questions.
What is not proven? Same net benefit for every assay and region; reduction to a single NCT.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
NCT05384769 is an example record; CIRCULATE ecosystem has multiple substudies. Registry status needs re-verification.
Cancer / population: Colon, Rectum — Rezeke kolorektal kanser (protokol kollarına göre)
Intervention: ctDNA güdümlü adjuvan / izlem stratejileri (GALAXY/VEGA/ALTAIR vb.)
Primary endpoint: Protokol kollarına göre DFS / nüks
Limitations: Platform karmaşıklığı; tek sonuç kartı yanıltıcı olabilir.